Japan's Takeda Pharmaceutical won early U.S. Food and Drug Administration approval for ixazomib (Ninlaro) to treat multiple myeloma ahead of its scheduled PDUFA review in March next year, the company said in a press release. The approval is for use of ixazomib in combination with Celgene's ($CELG) Revlimid and dexamethasone in patients already treated by first-line therapies. A launch could come as soon as next month. Ixazomib is also under accelerated review by the European Medicines Agency for relapsed multiple myeloma. Release